Li Pang M.D.

Research Biologist — Division of Systems Biology

Li Pang, M.D.
(870) 543-7121
NCTRResearch@fda.hhs.gov

Back to NCTR Principal Investigators page

Background

Dr. Pang earned an M.D. from North China Coal Medical College and completed her training in endocrinology at the Peking Union Medical College Hospital, Chinese Academy of Medical Sciences. She began her research journey in the domain of cardiovascular science, studying ion channel remodeling in heart failure and atrial fibrillation at the Montreal Heart Institute. Subsequently, she joined the University of Arkansas for Medical Sciences as a faculty member in the Department of Pharmacology and Toxicology, where she secured funding from the National Institutes of Health for her pioneering research on long-term hypertension therapy.

Dr. Pang began as a commissioner’s fellow with the FDA in 2011 before becoming a staff fellow with FDA’s National Center for Toxicological Research (NCTR) in 2013. Presently, she serves as a research biologist in the Division of Systems Biology, spearheading multiple projects aimed at improving the prediction of cardiovascular toxicity of FDA-regulated products primarily using in vitro models. Dr. Pang received the NCTR Director's Award in 2015 and 2018 and an FDA Center for Drug Evaluation and Research Director's Special Citation Award in 2018.

Research

Dr. Pang’s research interests include ion channel remodeling in cardiovascular disease, pharmacogenetics, gene therapy, and biomarker identification. Her current research aims to enhance the agency's endeavors in predicting toxicology and cardiovascular safety, with a particular focus on aiding the assessment of in vitro cell-based models for cardiovascular risk prediction.

Professional Societies/National and International Groups

Health and Environmental Sciences Institute (HESI) Cardiac Safety Committee
Member
2014 – Present

HESI Cardiac Stem Cell Working Group
Member
2014 – Present

Safety Pharmacology Society
Member
2016 – Present

Society of Toxicology
Member
2015 – Present

Selected Publications

Predicting Oncology Drug-Induced Cardiotoxicity with Donor-Specific iPSC-CMs—A Proof-of-Concept Study with Doxorubicin.
Pang L., Cai C., Aggarwal P., Wang D., Vijay V., Bagam P., Blamer J., Matter A., Turner A., Ren L., Papineau K., Srinivasasainagendra V., Tiwari H., Yang X., Schnackenberg L., Mattes W., and Broeckel U.
Toxicol Sci. 2024, 1-16. doi: 10.1093/toxsci/kfae041.

New Alternative Methods in Drug Safety Assessment.
Yang X., Shi Q., Chen M.J., and Pang L.
In: Jagadeesh G., Balakumar P., and Senatore F. (Eds) The Quintessence of Basic and Clinical Research and Scientific Publishing. 2023, 225-239. Springer, Singapore.

Use of Human iPSC-CMs in Nonclinical Regulatory Studies for Cardiac Safety Assessment.
Yang X., Ribeiro A., Pang L., and Strauss D.
Toxicol Sci. 2022, 190 (2), 117-126.

Effects of Serum and Compound Preparation Methods on Delayed Repolarization Evaluation with Human iPSC-CMs.
Wei F., Pence L., Woodling K., Bagam P., Beger R., Gamboa da Costa G., and Pang L.
Toxicol Sci. 2022, 188 (1), 48-61.

Improving Cardiotoxicity Prediction in Cancer Treatment: Integration of Conventional Circulating Biomarkers and Novel Exploratory Tools.
Pang L., Liu Z., Wei F., Cai C., and Yang X.
Arch Toxicol. 2021, 95(3):791-805. doi: 10.1007/s00204-020-02952-7.

Repolarization Studies Using Human Stem Cell-Derived Cardiomyocytes: Validation Studies and Best Practice Recommendations.
Gintant G., Kaushik E., Feaster T., Stoelzle-Feix S., Kanda Y., Osada T., Smith G., Czysz K., Kettenhofen R., Lu H., Cai B., Shi H., Herron T.J., Dang Q., Burton F., Pang L., Traebert M., Abassi Y., Pierson J., and Blinova K.
Regul Toxicol Pharmacol. 2020, 117:104756. doi: 10.1016/j.yrtph.2020.104756.

Toxicity Testing in the Era of Induced Pluripotent Stem Cells: A Perspective Regarding the Use of Patient-Specific Induced Pluripotent Stem Cell–Derived Cardiomyocytes for Safety Evaluation.
Pang L.
Current Opinion in Toxicology. 2020, 23, 50-55.

Effects of Electrical Stimulation on hiPSC-CM Responses to Classic Ion Channel Blockers.
Wei F., Pourrier M., Strauss D., Stockbridge N., and Pang L.
Toxicol Sci. 2020, 174(2):254-265. doi: 10.1093/toxsci/kfaa010.

Workshop Report: FDA Workshop on Improving Cardiotoxicity Assessment with Human-Relevant Platforms.
Pang L., Sager P., Yang X., Shi H., Sannajust F., Brock M., Wu J.C., Abi-Gerges N., Lyn-Cook B., Berridge B.R., and Stockbridge N.
Circ Res. 2019, 125(9):855-867. doi: 10.1161/CIRCRESAHA.119.315378.

International Multisite Study of Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Drug Proarrhythmic Potential Assessment.
Blinova K., Dang Q., Millard D., Smith G., Pierson J., Guo L., Brock M., Lu H., Kraushaar U., Zeng H., Shi H., Zhang X., Sawada K., Osada T., Kanda Y., Sekino Y., Pang L., Feaster T., Kettenhofen R., Stockbridge N., Strauss D., and Gintant G.
Cell Rep. 2018, 24(13):3582-3592. doi: 10.1016/j.celrep.2018.08.079.

Sex-Related Differences in Drug-Induced QT Prolongation and Torsades de Pointes: A New Model System with Human iPSC-CMs.
Huo J., Wei F., Cai C., Lyn-Cook B., and Pang L.
Toxicol Sci. 2018, doi: 10.1093/toxsci/kfy239.

Evaluation of Batch Variations in Induced Pluripotent Stem Cell-Derived Human Cardiomyocytes from 2 Major Suppliers.
Huo J., Karmalakar A., Yang X., Word B., Stockbridge N., Lyn-Cook B., and Pang L.
Toxicol Sci. 2017, 156(1):25-38. doi: 10.1093/toxsci/kfw235.

Comprehensive Translational Assessment of Human Induced Pluripotent Stem Cell Derived Cardiomyocytes for Evaluating Drug-Induced Arrhythmias.
Blinova K. Stohlman J., Vicente J., Chan D., Johannesen L., Hortigon-Vinagre M.P., Zamora V., Smith G., Crumb W.J., Pang L., Lyn-Cook B., Ross J., Brock M., Chvatal S., Millard D., Galeotti L., Stockbridge N., and Strauss D.
Toxicol Sci. 2017, 155(1):234-247. doi: 10.1093/toxsci/kfw200.

MicroRNA-Mediated Maturation of Human Pluripotent Stem Cell-Derived Cardiomyocytes: Towards a Better Model for Cardiotoxicity?
White M.C., Pang L., and Yang X.
Food Chem Toxicol. 2016, 98(Pt A):17-24. doi: 10.1016/j.fct.2016.05.025.

Reversal of MicroRNA Dysregulation in an Animal Model of Pulmonary Hypertension.
Gubrij I.B., Pangle A.K., Pang L., and Johnson L.G.
PLoS One. 2016, 11(1):e0147827. doi: 10.1371/journal.pone.0147827. eCollection 2016.

ATP-Binding Cassette Genes Genotype and Expression: A Potential Association with Pancreatic Cancer Development and Chemoresistance?
Pang L., Word B., Xu J., Wang H., Hammons G., Huang S.M., and Lyn-Cook B.
Gastroenterol Res Pract. 2014, 2014:414931. doi: 10.1155/2014/414931.

Vascular Smooth Muscle-Specific Knockdown of the Noncardiac Form of the L-type Calcium Channel by MicroRNA-Based Short Hairpin RNA as a Potential Antihypertensive Therapy.
Rhee S.W., Stimers J.R., Wang W., and Pang L.
J Pharmacol Exp Ther. 2009, 329(2):775-82. doi: 10.1124/jpet.108.148866.

Characterization of the Cardiac KCNE1 Gene Promoter.
Mustapha Z., Pang L., and Nattel S.
Cardiovasc Res. 2007, 73(1):82-91. doi: 10.1016/j.cardiores.2006.10.022.

Vascular-Specific Increase in Exon 1B-Encoded CAV1.2 Channels in Spontaneously Hypertensive Rats.
Wang W.Z., Saada N., Dai B., Pang L., and Palade P.
Am J Hypertens. 2006, 19(8):823-31. doi: 10.1016/j.amjhyper.2006.01.020.

Tissue-Specific Expression of Two Human Ca(v)1.2 Isoforms Under the Control of Distinct 5' Flanking Regulatory Elements.
Pang L., Koren G., Wang Z., and Nattel S.
FEBS Lett. 2003, 546(2-3):349-54. doi: 10.1016/s0014-5793(03)00629-x.

Lab Members

Contact information for all lab members:
(870) 543-7121
NCTRResearch@fda.hhs.gov

Prathyusha Bagam, Ph.D.
ORISE Fellow

Katy Papineau, B.S.
Biologist

Lijun Ren, M.D.
Staff Fellow

Contact Information: Li Pang; (870) 543-7121

Expertise: Expertise

Approach

Domain

Technology & Discipline

Toxicology